Suppr超能文献

口服抗凝剂治疗的心房颤动和慢性肾脏病G3 - G5D患者发生大出血的危险因素。

Risk factors for major bleeding in patients with atrial fibrillation and CKD G3-G5D on oral anticoagulants.

作者信息

Welander Frida, Renlund Henrik, Själander Anders

机构信息

Department of Public Health and Clinical Medicine, Department of Research and Development Sundsvall, Umeå University, Umeå, Sweden.

Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden.

出版信息

Clin Kidney J. 2024 Jul 5;17(8):sfae206. doi: 10.1093/ckj/sfae206. eCollection 2024 Aug.

Abstract

BACKGROUND

Patients with chronic kidney disease (CKD) and atrial fibrillation (AF) on oral anticoagulants (OACs) are at high risk of bleeding. Determinants of major bleeding risk in OAC users with AF and CKD are not well established and available bleeding score systems do not perform well in CKD. This study aims to present risk factors associated with major bleeding in a Swedish cohort of OAC-treated patients with CKD G3-5D.

METHODS

We conducted a Swedish register-based cohort study including patients with AF and CKD G3-5D on warfarin or direct OACs (DOACs) between 2009 and 2018. Data were collected from high-quality registers including the Swedish Renal Registry and Auricula, a register for AF and OACs. Risk factors for major bleeding were investigated with Cox regression analysis.

RESULTS

Of 2453 included patients, 59% were on warfarin (time in therapeutic range 67%) and 41% on DOACs. Major bleeding rates were 8.9/100 patient-years. Factors associated with increased bleeding risk were glomerular filtration rate category, G5/5D versus G3 {hazard ratio [HR] 1.92 [95% confidence interval (CI) 1.43-2.56]}, previous gastrointestinal bleeding [HR 1.77 (95% CI 1.39-2.25)], previous other bleeding [HR 1.33 (95% CI 1.09-1.62)], congestive heart failure [HR 1.36 (95% CI 1.11-1.68)], male sex [HR 1.28 (95% CI 1.03-1.60)] and vascular disease [HR 1.35 (95% CI 1.01-1.79)].

CONCLUSION

Patients with AF and G3-5D on OACs are at a high risk of bleeding. Previous major bleeding and kidney failure are strongly associated with major bleeding. The present study also shows an association between OAC-associated bleeding and male sex, congestive heart failure and vascular disease. Knowledge about determinants of bleeding in advanced CKD is essential when deciding on when to anticoagulate or not.

摘要

背景

患有慢性肾脏病(CKD)且正在服用口服抗凝药(OAC)的心房颤动(AF)患者出血风险很高。AF合并CKD的OAC使用者发生大出血风险的决定因素尚未明确确立,现有的出血评分系统在CKD患者中效果不佳。本研究旨在呈现瑞典一组接受OAC治疗的CKD G3 - 5D患者中与大出血相关的危险因素。

方法

我们开展了一项基于瑞典登记系统的队列研究,纳入了2009年至2018年间服用华法林或直接口服抗凝药(DOAC)的AF合并CKD G3 - 5D患者。数据收集自包括瑞典肾脏登记系统和Auricula(一个AF和OAC登记系统)在内的高质量登记系统。采用Cox回归分析研究大出血的危险因素。

结果

在纳入的2453例患者中,59%服用华法林(治疗范围内时间为67%),41%服用DOAC。大出血发生率为8.9/100患者年。与出血风险增加相关的因素包括肾小球滤过率类别,G5/5D对比G3 {风险比[HR] 1.92 [95%置信区间(CI)1.43 - 2.56]}、既往胃肠道出血[HR 1.77(95% CI 1.39 - 2.25)]、既往其他出血[HR 1.33(95% CI 1.09 - 1.62)]、充血性心力衰竭[HR 1.36(95% CI 1.11 - 1.68)]、男性[HR 1.28(95% CI 1.03 - 1.60)]和血管疾病[HR 1.35(95% CI 1.01 - 1.79)]。

结论

服用OAC的AF合并G3 - 5D患者出血风险很高。既往大出血和肾衰竭与大出血密切相关。本研究还显示OAC相关出血与男性、充血性心力衰竭和血管疾病之间存在关联。在决定是否进行抗凝治疗时,了解晚期CKD患者出血的决定因素至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfc6/11483581/2548db54d4f9/sfae206fig1g.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验